Key Performance
More- Earnings Score: 43
- Momentum Score: 23
- True Yield: N/A
- Financial Health Score: 5
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider
The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.
06/19/2026, 5:39 AM • GlobeNewswire
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Myriad Genetics announced a partnership with Netflix actress Jackie Tohn to promote awareness about hereditary cancer testing through the MyRisk® Hereditary Cancer Test. Tohn discovered she carried a BRCA1 gene variant and underwent preventive measures after learning she had an 85% risk of breast cancer and 65% risk of ovarian cancer. The MyRisk test evaluates 63 genes across 11 cancer types and is available through healthcare providers or virtual care.
05/15/2026, 11:00 AM • GlobeNewswire
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight
The cervical cancer diagnostics market is projected to grow from USD 4.4 billion in 2025 to USD 7.1 billion by 2034 at a CAGR of ~5%. Growth is driven by rising cervical cancer prevalence, increasing adoption of advanced diagnostic technologies like HPV testing and AI-powered screening tools, government screening initiatives, and expanding healthcare infrastructure particularly in emerging economies. North America leads the market with 44% share in 2025.
05/14/2026, 1:00 PM • GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Myriad Genetics announced the advancement of its Precise MRD product toward a March 2026 launch, supported by new breast and colorectal cancer study data demonstrating ultrasensitive ctDNA detection. The company also released select preliminary fourth quarter and full year 2025 financial results and provided full year 2026 financial guidance.
02/16/2026, 4:15 PM • GlobeNewswire
Decoding Our DNA: The Human Impact Behind SNP Genotyping’s USD 19.48 Billion Growth by 2034
The global single nucleotide polymorphism (SNP) genotyping market is valued at USD 8.08 billion in 2026 and is expected to reach USD 19.48 billion by 2034, growing at an 11.7% CAGR. North America leads the market while Asia Pacific shows the fastest growth. PCR-based genotyping dominates by technology, pharmacogenomics leads by application, and pharmaceutical companies are the primary end users. Key drivers include personalized medicine adoption, technological advancements, and increased genomics research investments.
02/13/2026, 10:00 AM • GlobeNewswire
The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.
01/30/2026, 4:57 AM • GlobeNewswire
The pan-genomic and multi-gene panel testing market is projected to grow from US$ 8.9 billion in 2024 to US$ 25.9 billion by 2032, driven by a 12.04% CAGR. Growth is fueled by rising clinical adoption of genomics-driven diagnostics, FDA approvals of comprehensive genomic profiling tests, advances in NGS technology and bioinformatics, and expanding implementation across oncology, rare diseases, and preventive medicine. North America leads the market while Asia-Pacific shows the fastest growth.
01/16/2026, 5:58 AM • GlobeNewswire
The global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. North America leads with 40.5% market share, while Asia Pacific is the fastest-growing region.
12/30/2025, 10:00 AM • GlobeNewswire
4D Path developed a computational platform that can predict chemotherapy response in early-stage triple-negative breast cancer using routine biopsy images, demonstrating potential for personalized cancer treatment prediction.
12/03/2025, 10:00 AM • GlobeNewswire
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
Myriad Genetics added F8 and FXN genes to its Foresight® Carrier Screen Universal Plus Panel, enhancing genetic screening capabilities for hemophilia A and Friedreich's ataxia, while maintaining compliance with ACMG recommendations.
10/14/2025, 8:00 AM • GlobeNewswire
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
Myriad Genetics published a study in The Lancet Oncology demonstrating the effectiveness of their Precise® MRD test in detecting circulating tumor DNA levels in patients with oligometastatic clear-cell renal cell carcinoma, potentially enabling treatment de-escalation.
09/04/2025, 7:00 PM • GlobeNewswire
Genetic Material Market Size, Trends and Top Companies (2025 – 2034 Forecast Period)
The genetic material market is expected to experience substantial growth driven by advancements in gene therapies, personalized medicine, and biopharmaceutical research. North America leads the market in 2024, with Asia Pacific projected to be the fastest-growing region from 2025-2034.
08/28/2025, 11:00 AM • GlobeNewswire
Global Liquid Biopsy Market Set to Reach USD 7.05 Billion by 2030 | MarketsandMarkets™
The global liquid biopsy market is projected to grow from $4.03 billion in 2025 to $7.05 billion by 2030, driven by rising cancer incidence, precision medicine advancements, and technological innovations in early disease detection.
08/22/2025, 9:00 AM • GlobeNewswire
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
A survey reveals that while 80% of women are afraid of health screenings, 75% would find genetic testing reassuring. Over 50% of high-risk women would feel empowered by advanced cancer screening methods, though only 14% have undergone genetic testing.
08/13/2025, 8:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.